Can I, as the patient’s primary care physician, continue prescribing docusate sodium (Colace) 250 mg once daily for a 54‑year‑old individual with well‑controlled diabetes and chronic constipation?

Do Not Continue Docusate (Colace) for Chronic Constipation

You should discontinue the docusate sodium (Colace) 250 mg daily and transition your patient to an evidence-based laxative regimen, as docusate has been shown to be ineffective for chronic constipation management.

Why Docusate Should Be Discontinued

The most recent and highest-quality guideline evidence explicitly states that docusate has not shown benefit and is therefore not recommended for constipation management 1. This 2019 NCCN guideline on adult cancer pain specifically addresses constipation treatment and clearly advises against docusate use based on available literature.

Multiple research studies confirm this lack of efficacy:

• A 2021 systematic review found that docusate showed no differences compared with placebo and was less effective than both psyllium and sennosides 2
• A 2022 study of post-surgical patients showed 79.9% treatment failure with docusate monotherapy 3
• A 2021 critical analysis concluded that docusate recommendations in major guidelines are "weakly evidence based" and institutions should consider removing it from protocols 4

What You Should Prescribe Instead

Based on the 2023 AGA-ACG guideline for chronic idiopathic constipation 5, here is your evidence-based approach:

First-Line Options:

1. Polyethylene glycol (PEG) - Start with 17g (1 capful) in 8 oz water once or twice daily
2. Bisacodyl - 10-15 mg daily, can titrate up to three times daily with goal of one non-forced bowel movement every 1-2 days 6
3. Lactulose - 15-30 mL (10-20g) daily, can increase to 60 mL daily if needed 5

For Your Diabetic Patient Specifically:

The diabetes connection is important here. Guidelines specifically mention treating underlying causes including diabetes mellitus when managing constipation 6. Lactulose use in mildly constipated, non-insulin-dependent type 2 diabetic patients may not increase blood sugar levels 5, making it a reasonable option.

Implementation Strategy

Immediate action:

• Discontinue docusate 250 mg daily
• Start PEG 17g daily OR bisacodyl 10mg daily (bisacodyl is preferred if cost is a concern and patient can tolerate it)
• Counsel on lifestyle measures: increase fluids, increase dietary fiber only if adequate fluid intake, and exercise if appropriate 6

If inadequate response after 2-4 weeks:

• Add a stimulant laxative (bisacodyl or senna) if not already using one
• Consider switching to or adding lactulose
• Reassess for impaction, obstruction, or worsening glycemic control

Rescue therapy:

• Keep bisacodyl 10mg available for PRN use if using PEG as maintenance
• Consider glycerin suppositories for acute relief

Common Pitfalls to Avoid

1. Don't continue docusate just because "it's been working" - The patient's subjective improvement may be due to natural variation, dietary factors, or placebo effect. The evidence clearly shows docusate is no better than placebo 2

2. Don't use docusate monotherapy even as an adjunct - Studies show adding docusate to senna provides no additional benefit 6. You're adding cost and pill burden without therapeutic gain

3. Don't prescribe fiber supplements without ensuring adequate hydration - Supplemental medicinal fiber like psyllium is ineffective and may worsen constipation 1

4. Watch for the most common side effect with bisacodyl - Abdominal cramping and pain. Start at lower doses (5-10mg) and titrate up as tolerated 5

The Deprescribing Opportunity

A 2016 study found that 87% of hospitalized patients already on docusate had it continued on discharge, representing significant missed deprescribing opportunities 7. Your patient has been on an ineffective medication for years - this is an ideal time to optimize their regimen with evidence-based therapy.

The 2016 NCCN palliative care guidelines only mention docusate in the context of end-of-life care (weeks to days life expectancy) as part of combination therapy with senna 6, not for chronic management in ambulatory patients with years of life expectancy.

Your patient deserves effective treatment. Transition to PEG or bisacodyl with appropriate counseling on lifestyle modifications and follow up in 2-4 weeks to assess response.